.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,368,632

« Back to Dashboard

Claims for Patent: 6,368,632

Title: Microencapsulated 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
Abstract:Method of treating warm blooded animals suffering from psychotic disorders. The method includes administering a pharmaceutically effective amount of sustained-release microparticles that include risperidone, or a pharmaceutically acceptable acid addition salt thereof, and a biodegradable and biocompatible polymeric matrix.
Inventor(s): Mesens; Jean (Wechelderzande, BE), Rickey; Michael E. (Loveland, OH), Atkins; Thomas J. (York, PA)
Assignee: Janssen Pharmaceutica (Beerse, BE) Alkermes Controlled Therapeutics Inc. II (Cambridge, MA)
Application Number:09/578,908
Patent Claims: 1. A method of treating warm blooded animals suffering from psychotic disorders comprising the administration thereto of a pharmaceutically effective amount of sustained-release microparticles produced by dissolving in a solvent an active agent and a biodegradable and biocompatible polymer to form an organic phase, wherein the active agent is selected from the group consisting of risperidone, 9-hydroxy-risperidone, and pharmaceutically acceptable acid addition salts of the foregoing, and extracting the solvent to form microparticles.

2. A method of treating warm blooded animals suffering from psychotic disorders comprising the administration thereto of a pharmaceutically effective amount of sustained-release microparticles comprising risperidone, or a pharmaceutically acceptable acid addition salt thereof, in crystalline form, and a biodegradable and biocompatible polymeric matrix.

3. The method of claim 1, wherein the microparticles range in size from 1 to 500 microns.

4. The method of claim 2, wherein the microparticles range in size from 1 to 500 microns.

5. The method of claim 1, wherein the microparticles range in size from 25 to 180 microns.

6. The method of claim 2, wherein the microparticles range in size from 25 to 180 microns.

7. The method of claim 1, wherein the microparticles are formulated in a liquid injection vehicle.

8. The method of claim 2, wherein the microparticles are formulated in a liquid injection vehicle.

9. The method of claim 7, wherein the liquid injection vehicle is selected from the group consisting of physiological saline solution and an aqueous solution of carboxymethyl cellulose with a surfactant.

10. The method of claim 8, wherein the liquid injection vehicle is selected from the group consisting of physiological saline solution and an aqueous solution of carboxymethyl cellulose with a surfactant.

11. The method of claim 1, wherein the microparticles are administered by intra-muscular injection.

12. The method of claim 2, wherein the microparticles are administered by intra-muscular injection.

13. The method of claim 1, wherein the microparticles are administered by subcutaneous injection.

14. The method of claim 2, wherein the microparticles are administered by subcutaneous injection.

15. The method of claim 3, wherein the microparticles comprise a plurality of sizes to provide for delivery of the active agent in a multi-phasic manner.

16. The method of claim 4, wherein the microparticles comprise a plurality of sizes to provide for delivery of the active agent in a multi-phasic manner.

17. The method of claim 1, wherein a portion of the microparticles exhibit diffusional release and a portion of the microparticles exhibit biodegradation release.

18. The method of claim 2, wherein a portion of the microparticles exhibit diffusional release and a portion of the microparticles exhibit biodegradation release.

19. The method of claim 17, wherein a portion of the microparticles exhibit both diffusional release and biodegradation release.

20. The method of claim 18, wherein a portion of the microparticles exhibit both diffusional release and biodegradation release.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc